«Publication Policies and Procedures for the Journals of the American Diabetes Association Last updated 30 October 2015 The American Diabetes Care ...»
Author’s Notes. Articles are posted individually after proofs are returned from authors and before appearing in an issue. To preserve the integrity of electronically publishing articles, once an article is individually posted but not yet in an issue, changes cannot be made in place in the paper. However, an “Author’s Note” may be added to the paper immediately before the References section when there is a critical error in the content of the paper. The “Author’s Note” section gives the author an opportunity to correct this type of critical error before the article is put into an issue for printing and before it is reposted in an issue. The “Author’s Note” section remains a permanent part of the article.
Retractions. The primary purposes of a retraction are to correct the literature, ensure its integrity, and alert readers to publications that contain erroneous and unreliable data or conclusions. ADA Journals will consider retracting a publication if there is clear evidence that the findings are unreliable, either as a result of misconduct (e.g., data fabrication) or honest error (e.g., miscalculation or experimental error);
if the findings have previously been published elsewhere without proper cross-referencing, permission, or justification; if significant portions of the paper have been plagiarized; if the paper reports unethical research; or if the authors fails to disclose a major competing interest likely to influence interpretations or recommendations.
The editors of ADA Journals will refer to the Retraction Guidelines of the Committee on Publication Ethics when considering whether to retract an article from publication. The editors may consult with the Association’s Panel on Ethical Scientific Publications (ESP) when reviewing retraction requests and recommendations. Recommendations may be forwarded to the American Diabetes Association, the publisher of ADA Journals, for final review and approval.
ADA Journals will make every effort to ensure that published retraction notices:
link to all electronic versions of the retracted article wherever possible clearly identify the retracted article by including the title and authors in the retraction heading are clearly identified as a retraction to distinguish it from other types of corrections or comments are published promptly to minimize the harmful effects from misleading publications are freely available to all readers Authors of submitted retraction notices should ensure that all coauthors listed on the original paper are aware of the problems with the paper and the pending retraction request. In cases where coauthors disagree, the editors will consult with the ESP to determine the most appropriate type of amendment;
dissenting author(s) will be noted in the text of the published amendment.
Retraction requests to ADA Journals should clearly state the following information:
the specific reasons and basis for the retraction (in order to distinguish cases of misconduct from those of honest error) who is retracting the article (e.g., the author; the head of the department, dean, or director of the laboratory where the paper was produced; or the editorial team of the journal) whether any coauthors do not agree with or support the request whether the issue was reviewed by the author(s)’ institution or funding agency.
If a previously published retraction statement is itself misleading or does not properly or fully disclose issues of misconduct (e.g., plagiarism or the republication of data or figures from previously published articles), ADA Journals will consider requests from authors or their affiliated institutions to publish an update to the retraction notice in order to better clarify or identify the problems with the retracted paper. Requests submitted by authors to update or emend retraction notices will be reviewed by the editorial team and the ESP. Updates to retraction notices should meet the guidelines and standards listed above.
Addenda. Addenda (or “updates”) communicate additional information to a paper, either by request of the author(s) or in response to readers' request for clarification. Addenda are published only rarely.
They will be reviewed by the editors to determine whether they are crucial to the reader's understanding of the published paper.
Addenda should be signed by all authors. They will be published in the print and online versions of the journal. Addenda are listed in the table of contents, are linked online to the articles to which they pertain, and are indexed in public databases such as PubMed.
Media Embargos Other than reporting on details provided in a meeting abstract or meeting presentation, media representatives should refrain from reporting on studies submitted to or scheduled for publication in ADA Journals until that study has completely undergone the peer-review and editorial processes, and has been either posted on the journal website or published in the print version of the journal. Authors are discouraged from holding press conferences to publicize abstract results until their submitted manuscripts have completely undergone the peer-review and editorial processes.
Advertising Both electronic and print advertising submitted to ADA publications is reviewed by the Association’s Scientific & Medical Department. The ADA has the right to reject any advertisement for any reason, which need not be disclosed to the party submitting the advertisement. Advertising submitted to ADA publications should clearly identify the advertiser and the product or service being offered. If the advertisement promotes a pharmaceutical product, the full generic name of each active ingredient in the drug product should be clearly listed. ADA Journals will not deliberately place print or electronic advertising opposite or adjacent to editorial that discusses the product being advertised or that reports research on the advertised product, and ADA Journals will not publish advertisements that refer to an article in the same issue of a publication. Advertising submitted to ADA publications should be distinct from editorial and should not appear to be editorial; advertising must not be deceptive or misleading or make false claims. Any advertisements that include indecent copy or contain negative content of a personal, racial, ethnic, medical, sexual orientation, or religious character will not be accepted.
Solicitation of advertising for ADA publications will be carried out to fulfill the objective of supporting awareness among health professionals and consumers of useful products and services and to contribute to the financial support of the publications. Acceptance of advertising in ADA publications shall not be construed, however, as an endorsement, approval, recommendation, warranty or certification of the products or services by ADA or any group affiliated with it. Acceptance also does not imply responsibility on the part of ADA to ensure that the advertiser has complied with laws and regulations applicable to the marketing of the products. Acceptance of advertising does not imply that ADA has conducted an independent scientific review to validate product safety and efficacy or advertising claims. A company involved in an investigation or enforcement proceeding by a government agency with respect to claims made in marketing of a product to be advertised in an ADA publication must inform ADA of such litigation.
Products or services must be safe and effective in the practice of medicine or to individuals with diabetes and their families. A company whose product submitted for advertisement in an ADA journal is being evaluated for safety and effectiveness must so inform the ADA.
Companies submitting new products for advertisement may be required to provide information about product safety and effectiveness. If there is any question of safety or effectiveness, the appropriate staff person in the Scientific & Medical Division should see a product sample before acceptance/rejection.
Advertisements for products that are subject to regulation by the Food & Drug Administration (FDA) will be accepted in ADA publications only if the products have met all FDA requirements to permit general marketing of the products.
Advertisements for products subject to FDA approval of both the product and the advertising may be accepted in ADA publications without further review.
Manufacturers whose products are subject to regulation by the FDA or Federal Trade Commission may be asked to submit a signed certification to ADA attesting that they have scientifically valid data on file to substantiate product claims or comparisons to other products.
Companies submitting advertisements for ADA publications are required to indemnify the Association against claims based on the advertisements.
Supplements Editorial Supplements which are developed by non-profit groups, but sponsored by a pharmaceutical or other company, may be considered to be “under the cover of” one of ADA’s professional journals (either within an issue or bound separately) if approved in advance by the Association’s Scientific & Medical Department and the Editor-in-Chief of the journal. If approved, the journal Editor may appoint a special supplement editor to lead the journal’s peer-review process. The supplement editor should be affiliated with ADA and should be an expert on the supplement topic. Approved Editorial Supplements should be completed prior to transition of a new Editor and editorial team for the journal.
Supplements proposals for ADA Journals should include a planned table of contents or, if based on a
meeting or symposium, a planned agenda. The proposal should also address:
The name of the organization(s) sponsoring and funding the supplement (not merely the name of the public relations agency handling its publication).
If the supplement is based on a symposium, where and when the symposium was held and how the speakers and papers were selected.
Whether authors were or will be paid and, if so, how much.
If the proposal is approved, it will be forwarded to the Editor of the journal. Initial approval by the ADA does not commit the Editor to accept a proposal in whole or part. All manuscripts are subject to the same peer review as other manuscripts in the journal. In addition, ADA has adopted the following principles from ICMJE, as outlined in section III-F of ICMJE’s Recommendations for the Conduct,
Reporting, Editing, and Publication of Scholarly Work in Medical Journals:
The journal editor has complete control of the decision to publish all or any portions of the supplement. Editing by the funding organization is not permitted.
The journal editor retains the authority to send supplement manuscripts for external peer review and to reject manuscripts submitted for the supplement.
The journal editor must approve the appointment of any external editor of the supplement and take responsibility for the work of the external editor.
The sources of funding for the research, publication, and the products the funding source make that are considered in the supplement must be clearly stated and prominently located in the supplement, preferably on each page.
Advertising in supplements follow the same policies as those of the rest of the journal.
Journal editors and supplement editors may not accept personal favors or personal remuneration from sponsors of supplements.
Secondary publication in supplements (republication of papers previously published elsewhere) is not permitted.
ADA’s principles of authorship, potential conflict-of-interest disclosure, and other publication policies also apply to supplements.
Advertising Supplements may be accepted if they meet the following criteria:
They do not carry ADA’s name or logo.
They are not formatted to suggest that they are part of one of ADA’s periodicals.
They are clearly labeled as advertising.
They are reviewed and approved by the Editor-in-Chief of the periodical in question, as well as the appropriate ADA staff member.
Questions Questions about any of the policies mentioned above should be directed to ADA’s editorial office at